A total of 119 patients were eligible for this study. Mean values of patient age, BMI, prostatic volume, and PSA were 65 years, 23.6 kg/m2, 28.7 mL, and 9.4 ng/mL, respectively. Nerve sparing was performed bilaterally or unilaterally in 51 patients. Total IPSS score was mild or moderate in 105, and severe in 14 patients before RARP. Mean compliance, mean first desire to void, mean strong desire to void, and mean PdetQmax were 59.6 ml/cmH2O, 152.4 ml, 282.9 ml and 46.6, respectively. DO was identified in 10 patients. The number of patients in Groups 1 and 2 were 71 and 48, respectively. Preoperatively, prostate volume in Group 2 was higher than in Group 1 (24.8 ml vs. 35.8 ml, p<0.05). Similarly, Group 2 patients had higher total IPSS scores (6.8 vs. 9.9, p<0.05) and IPSS-voiding symptom scores (3.7 vs. 6.1 p<0.05) than Group 1 patients. After RARP, there were no significant differences in total IPSS scores, IPSS-voiding symptom scores, IPSS-storage symptom scores, OABSS and QOL index (Figure 1) between the two groups. The rate of achieving zero-pad urinary continence was significantly different between Groups 1 and 2 at one month post-RARP, but after three months, there was no difference between them (Figure 1). Univariate and multivariate logistic regression analyses revealed only nerve sparing and FDV after one month, nerve sparing and membranous urethra width to be significantly associated with continence 12 months post-RARP. However, IPP tended to be involved in urinary incontinence for one month after RARP, although no significant difference was observed between the two groups (Table 1).